Vertex Pharmaceuticals (VRTX) News Today → Guard Against the Coming Financial Upheaval (From Porter & Company) (Ad) Free VRTX Stock Alerts $445.21 +4.57 (+1.04%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 3:29 PM | marketbeat.comRobeco Institutional Asset Management B.V. Sells 187,749 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Robeco Institutional Asset Management B.V. reduced its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 43.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 245,188 shares of the pharmaceutical company's stock after seMay 19 at 7:13 AM | marketbeat.comVertex Pharmaceuticals Q1 Earnings TranscriptMay 19 at 3:50 AM | americanbankingnews.comVertex Pharmaceuticals (NASDAQ:VRTX) Raised to Strong-Buy at StockNews.comMay 19 at 3:50 AM | marketbeat.comVertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Vertex Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday.May 18 at 8:28 PM | marketbeat.comSecurian Asset Management Inc. Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Securian Asset Management Inc. lessened its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 11.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,324 shares of the pharmaceuticalMay 17 at 9:51 PM | marketbeat.comEFG Asset Management North America Corp. Buys 2,502 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)EFG Asset Management North America Corp. grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 51.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,340 shares of theMay 16 at 2:24 PM | marketbeat.comInceptionr LLC Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Inceptionr LLC cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 69.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 819 shares of the pharmaceutical company's stocMay 15, 2024 | nz.finance.yahoo.comJennifer Schneider Elected to Vertex Board of DirectorsMay 15, 2024 | benzinga.comVertex Pharmaceuticals's Options Frenzy: What You Need to KnowMay 15, 2024 | marketbeat.comFirst Turn Management LLC Invests $33.24 Million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)First Turn Management LLC bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 81,683 shares of the pharmaceutical comMay 14, 2024 | marketbeat.com14,068 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Torray Investment Partners LLCTorray Investment Partners LLC acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 14,068 shares of the pharmaceutical company's stock, valued aMay 14, 2024 | finance.yahoo.comVertex Stock Hit All-Time High, Paused, Rising AgainMay 14, 2024 | investorplace.com3 Cheap Biotech Stocks to Buy Now: May 2024May 13, 2024 | marketbeat.comPrincipal Financial Group Inc. Buys 40,005 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Principal Financial Group Inc. raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 12.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 368,728 shares of the pharmaceutical company's stockMay 12, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Sells 265,992 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Massachusetts Financial Services Co. MA decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 6.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,625,802 shares of the pharmaceutiMay 12, 2024 | fool.comVertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart BuyMay 12, 2024 | fool.com2 Unbelievable Growth Stocks You Can Buy and Hold for the Next DecadeMay 11, 2024 | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Teacher Retirement System of TexasTeacher Retirement System of Texas cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 11.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 60,343 shares of theMay 11, 2024 | americanbankingnews.comVertex Pharmaceuticals (NASDAQ:VRTX) Downgraded by StockNews.comMay 10, 2024 | finance.yahoo.comAlpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ...May 10, 2024 | marketbeat.comWill the Biotech Sector Shift From Lagger to Leader?The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).May 10, 2024 | marketbeat.comWill the Biotech Sector Shift From Lagger to Leader? (VRTX)The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs.May 9, 2024 | marketbeat.comBronte Capital Management Pty Ltd. Acquires New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Bronte Capital Management Pty Ltd. purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 20,760 shares of the pharmaceMay 9, 2024 | businesswire.comAlpine Immune Sciences Reports First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comResults: Vertex Pharmaceuticals Incorporated Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 9, 2024 | americanbankingnews.comVertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Reaffirmed by HC WainwrightMay 9, 2024 | americanbankingnews.comPiper Sandler Increases Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $456.00May 9, 2024 | americanbankingnews.comVertex Pharmaceuticals (NASDAQ:VRTX) Rating Reiterated by Needham & Company LLCMay 8, 2024 | marketbeat.comBarlow Wealth Partners Inc. Purchases New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Barlow Wealth Partners Inc. bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 44,966 shares of the pharmaceutical company'May 8, 2024 | stocknews.comVertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?May 8, 2024 | markets.businessinsider.comSell Rating on Vertex Pharmaceuticals Amid Non-Recurring Gains and Overstated SalesMay 8, 2024 | fool.com5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the DipMay 7, 2024 | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,509,206 shares of the pharmaceutical company's stockMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vertex Pharmaceuticals on Strong Q1 Earnings and Expanding Market PresenceMay 7, 2024 | finance.yahoo.comQ1 2024 Vertex Pharmaceuticals Inc Earnings CallMay 7, 2024 | finance.yahoo.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finance.yahoo.comVertex's Pain Drug Could Be Worth Up To $11.4 Billion — Ongoing Debate Sparks SharesMay 7, 2024 | marketbeat.comNeedham & Company LLC Reiterates "Hold" Rating for Vertex Pharmaceuticals (NASDAQ:VRTX)Needham & Company LLC reissued a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday.May 6, 2024 | marketbeat.comWelch & Forbes LLC Grows Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Welch & Forbes LLC grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 1.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 188,387 shares of the pharmaceutical company's stockMay 6, 2024 | msn.comVRTX Stock Earnings: Vertex Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | finance.yahoo.comUPDATE 1-Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatmentsMay 6, 2024 | fool.comVertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call TranscriptMay 6, 2024 | marketbeat.comVertex Pharmaceuticals (NASDAQ:VRTX) Announces Earnings Results, Beats Expectations By $1.15 EPSVertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) issued its earnings results on Monday. The pharmaceutical company reported $4.76 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $1.15. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm had revenue of $2.69 billion during the quarter, compared to the consensus estimate of $2.58 billion. During the same quarter in the previous year, the firm posted $2.67 earnings per share. The company's revenue was up 13.3% compared to the same quarter last year.May 6, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, May 06, 2024May 6, 2024 | benzinga.comSmart Money Is Betting Big In VRTX OptionsMay 6, 2024 | finance.yahoo.comVertex Reports First Quarter 2024 Financial ResultsMay 6, 2024 | finance.yahoo.comVertex tops Q1 profit estimates on robust demand for cystic fibrosis treatmentsMay 6, 2024 | reuters.comVertex tops Q1 profit estimates on robust demand for cystic fibrosis treatmentsMay 6, 2024 | businesswire.comVertex Reports First Quarter 2024 Financial ResultsMay 6, 2024 | investorplace.com3 Biotech Stocks to Double Your Money in the Next 24 Months Get Vertex Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Guard Against the Coming Financial Upheaval (Ad)America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late. You can stream it for free right here. VRTX Media Mentions By Week VRTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRTX News Sentiment▼0.970.42▲Average Medical News Sentiment VRTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRTX Articles This Week▼1513▲VRTX Articles Average Week Get Vertex Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Regeneron Pharmaceuticals News Sanofi News GSK News Bristol-Myers Squibb News Zoetis News Pfizer News Takeda Pharmaceutical News Abbott Laboratories News Royalty Pharma News BeiGene News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRTX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaUrgent Nvidia WarningAltimetryThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
